Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study
- 24 September 2013
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 70 (1) , 99-108
Abstract
Purpose To describe the clinical profile of the patients that initiate statin therapy for the primary prevention of vascular diseases and to investigate the extent to which clinicians use intensive vs. standard regimens. Methods A cross-sectional analysis of nationwide individual data regarding individuals ≥11 years with a first prescription of statin, recorded between 1 January 2007 and 31 December 2011. Subjects were defined as intensive therapy initiators if a statin dose superior to simvastatin 40 mg (or equivalent dose if different statin) was first prescribed. Multivariable logistic regression models were built for dependent summary variables to evaluate the strength of the association between them and the use of intensive therapy. Results Overall, 69,737 patients receiving a first prescription of statin for the primary prevention of vascular diseases were identified. Predictors for intensive therapy initiation were male gender (adjusted OR: 1.28; 95%CI: 1.10–1.48), history of hypothyroidism (1.47; 1.17–1.85), current treatment of diabetes (1.18; 1.00–1.41), proteinuria (1.87; 1.12–3.12), age, and year of statin prescription. Modifiable risk factors associated with intensive therapy were elevated tryglicerides (1.63; 1.39–1.91), elevated LDL-C (1.96; 1.69–2.28), obesity (1.25; 1.07–1.47), smoking (1.32; 1.14–1.55), comedication with ezetimibe (3.76; 1.87–7.55), fibrates (1.96; 1.43–2.70) and calcium antagonists in women (1.42; 1.02–1.98). Conclusions The use of intensive therapy with statins in primary prevention was not very high in absolute terms, but is increasing considerably. The association between intensive therapy and previous hypothyroidism or its combination with fibrates may raise additional safety and tolerability concerns.Keywords
This publication has 36 references indexed in Scilit:
- When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of StatinsPLOS ONE, 2013
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)European Journal of Preventive Cardiology, 2012
- Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin EraCirculation, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialThe Lancet, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- Differences between clinical trials and postmarketing useBritish Journal of Clinical Pharmacology, 2003
- Treating dyslipidemia with statins: The risk-benefit profileAmerican Heart Journal, 2003
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994